Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HIV Infections | 13 | 2021 | 11620 | 0.96 | Why? |
| Democratic Republic of the Congo | 5 | 2020 | 500 | 0.88 | Why? |
| Artemisia | 1 | 2020 | 27 | 0.86 | Why? |
| Antibiotics, Antitubercular | 1 | 2019 | 65 | 0.79 | Why? |
| Hemorrhagic Fever, Ebola | 2 | 2020 | 1475 | 0.75 | Why? |
| Anti-HIV Agents | 4 | 2019 | 2209 | 0.72 | Why? |
| Rifampin | 1 | 2019 | 276 | 0.67 | Why? |
| Selection Bias | 1 | 2017 | 201 | 0.63 | Why? |
| Biomedical Technology | 1 | 2020 | 257 | 0.63 | Why? |
| Africa | 7 | 2021 | 2986 | 0.60 | Why? |
| Off-Label Use | 1 | 2020 | 553 | 0.59 | Why? |
| Armed Conflicts | 1 | 2018 | 209 | 0.56 | Why? |
| Tuberculosis, Multidrug-Resistant | 1 | 2019 | 433 | 0.54 | Why? |
| Tenofovir | 1 | 2017 | 449 | 0.53 | Why? |
| Anti-Retroviral Agents | 2 | 2021 | 1099 | 0.50 | Why? |
| Measles | 1 | 2020 | 608 | 0.48 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2021 | 10649 | 0.45 | Why? |
| HIV | 3 | 2020 | 1116 | 0.43 | Why? |
| BCG Vaccine | 1 | 2021 | 1137 | 0.42 | Why? |
| Mass Vaccination | 1 | 2021 | 1101 | 0.42 | Why? |
| Metabolic Syndrome | 1 | 2018 | 810 | 0.41 | Why? |
| Mycobacterium tuberculosis | 1 | 2019 | 1164 | 0.41 | Why? |
| Africa South of the Sahara | 4 | 2021 | 1335 | 0.40 | Why? |
| Pregnancy Complications, Infectious | 4 | 2020 | 11559 | 0.40 | Why? |
| Premature Birth | 2 | 2020 | 2151 | 0.38 | Why? |
| Plant Extracts | 1 | 2020 | 1514 | 0.38 | Why? |
| Tuberculosis, Pulmonary | 1 | 2019 | 1171 | 0.38 | Why? |
| Tuberculosis | 2 | 2021 | 2895 | 0.35 | Why? |
| Immunization Programs | 1 | 2021 | 2006 | 0.35 | Why? |
| Research | 1 | 2020 | 2115 | 0.34 | Why? |
| Attitude to Health | 1 | 2021 | 2002 | 0.34 | Why? |
| Contact Tracing | 3 | 2021 | 8448 | 0.32 | Why? |
| Warfare | 1 | 2006 | 90 | 0.30 | Why? |
| Infectious Disease Transmission, Vertical | 2 | 2020 | 5164 | 0.26 | Why? |
| Morbidity | 2 | 2021 | 1426 | 0.25 | Why? |
| Patient Safety | 1 | 2017 | 4885 | 0.23 | Why? |
| Developing Countries | 1 | 2018 | 4283 | 0.23 | Why? |
| Rwanda | 1 | 2021 | 270 | 0.21 | Why? |
| Tuberculosis, Miliary | 1 | 2021 | 66 | 0.21 | Why? |
| Pregnancy | 6 | 2021 | 23879 | 0.21 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 533 | 0.20 | Why? |
| Epidemics | 1 | 2020 | 6407 | 0.20 | Why? |
| Uganda | 2 | 2021 | 1057 | 0.20 | Why? |
| Medication Adherence | 2 | 2019 | 1270 | 0.19 | Why? |
| Cross Protection | 1 | 2021 | 373 | 0.18 | Why? |
| Antimalarials | 2 | 2021 | 2505 | 0.18 | Why? |
| Pandemics | 12 | 2021 | 389249 | 0.18 | Why? |
| Sample Size | 1 | 2020 | 518 | 0.17 | Why? |
| Case Management | 1 | 2020 | 285 | 0.17 | Why? |
| South Africa | 4 | 2021 | 3326 | 0.17 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.17 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.17 | Why? |
| Humans | 33 | 2021 | 930598 | 0.16 | Why? |
| Mortality, Premature | 1 | 2018 | 111 | 0.16 | Why? |
| Nigeria | 2 | 2021 | 2292 | 0.16 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.16 | Why? |
| Infant, Low Birth Weight | 1 | 2017 | 243 | 0.15 | Why? |
| Psychotherapy, Group | 1 | 2017 | 134 | 0.15 | Why? |
| Birth Weight | 1 | 2017 | 250 | 0.15 | Why? |
| Self-Help Groups | 1 | 2017 | 163 | 0.15 | Why? |
| Organizations | 1 | 2017 | 201 | 0.15 | Why? |
| Medically Underserved Area | 1 | 2018 | 273 | 0.15 | Why? |
| Chloroquine | 2 | 2020 | 3152 | 0.15 | Why? |
| Azithromycin | 2 | 2020 | 3943 | 0.14 | Why? |
| Health Services | 1 | 2021 | 765 | 0.14 | Why? |
| Adolescent Health | 1 | 2018 | 227 | 0.14 | Why? |
| Communicable Disease Control | 2 | 2021 | 29620 | 0.14 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.13 | Why? |
| Intersectoral Collaboration | 1 | 2020 | 1065 | 0.13 | Why? |
| Enoxaparin | 1 | 2020 | 1064 | 0.13 | Why? |
| Child | 7 | 2021 | 70012 | 0.12 | Why? |
| Infant, Newborn | 3 | 2020 | 23105 | 0.12 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.12 | Why? |
| Treatment Outcome | 6 | 2021 | 51732 | 0.12 | Why? |
| Drug Resistance, Viral | 1 | 2018 | 1083 | 0.11 | Why? |
| Sputum | 1 | 2019 | 1720 | 0.11 | Why? |
| Coinfection | 2 | 2021 | 6820 | 0.11 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.10 | Why? |
| Drug Resistance, Bacterial | 1 | 2019 | 1414 | 0.10 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.09 | Why? |
| Health Communication | 1 | 2020 | 1120 | 0.09 | Why? |
| Income | 1 | 2018 | 1564 | 0.09 | Why? |
| Homosexuality, Male | 1 | 2018 | 1158 | 0.09 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.09 | Why? |
| Prevalence | 3 | 2020 | 25773 | 0.09 | Why? |
| Female | 12 | 2021 | 380317 | 0.09 | Why? |
| Antiviral Agents | 2 | 2021 | 41703 | 0.09 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.09 | Why? |
| Urban Population | 1 | 2018 | 2000 | 0.09 | Why? |
| Health Promotion | 1 | 2021 | 2020 | 0.08 | Why? |
| Risk Factors | 4 | 2020 | 71621 | 0.08 | Why? |
| Pregnant Women | 1 | 2020 | 2535 | 0.08 | Why? |
| Patient Education as Topic | 1 | 2017 | 1476 | 0.08 | Why? |
| Hydroxychloroquine | 2 | 2021 | 12447 | 0.08 | Why? |
| Practice Guidelines as Topic | 2 | 2021 | 15421 | 0.08 | Why? |
| Renal Insufficiency, Chronic | 1 | 2020 | 2654 | 0.08 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.08 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Retrospective Studies | 4 | 2020 | 105322 | 0.07 | Why? |
| Antirheumatic Agents | 1 | 2020 | 3023 | 0.07 | Why? |
| Wounds and Injuries | 1 | 2018 | 1708 | 0.07 | Why? |
| Adult | 9 | 2021 | 244371 | 0.07 | Why? |
| Point-of-Care Testing | 1 | 2018 | 2782 | 0.07 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.07 | Why? |
| Pregnancy Outcome | 1 | 2017 | 3803 | 0.07 | Why? |
| Aging | 1 | 2020 | 3581 | 0.07 | Why? |
| International Cooperation | 1 | 2017 | 3436 | 0.07 | Why? |
| Adolescent | 5 | 2021 | 86841 | 0.06 | Why? |
| Biomedical Research | 2 | 2021 | 5270 | 0.06 | Why? |
| Socioeconomic Factors | 1 | 2020 | 8495 | 0.06 | Why? |
| HIV-1 | 1 | 2018 | 3365 | 0.06 | Why? |
| Communication | 1 | 2020 | 5206 | 0.06 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.06 | Why? |
| Education, Medical | 1 | 2017 | 2461 | 0.05 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.05 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.05 | Why? |
| Male | 8 | 2020 | 367725 | 0.05 | Why? |
| Operations Research | 1 | 2018 | 27 | 0.05 | Why? |
| United States | 3 | 2020 | 46150 | 0.04 | Why? |
| Global Health | 1 | 2021 | 13911 | 0.04 | Why? |
| Circumcision, Male | 1 | 2017 | 57 | 0.04 | Why? |
| Viral Load | 1 | 2018 | 15850 | 0.04 | Why? |
| Cultural Characteristics | 1 | 2017 | 159 | 0.04 | Why? |
| Cohort Studies | 1 | 2019 | 36005 | 0.04 | Why? |
| Prospective Studies | 1 | 2020 | 43301 | 0.04 | Why? |
| Middle Aged | 5 | 2020 | 270681 | 0.04 | Why? |
| Quality-Adjusted Life Years | 1 | 2018 | 511 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2018 | 6543 | 0.04 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Depression | 1 | 2017 | 14116 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.03 | Why? |
| Counseling | 1 | 2017 | 747 | 0.03 | Why? |
| Postpartum Period | 1 | 2017 | 936 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.03 | Why? |
| Incidence | 2 | 2017 | 25622 | 0.03 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Phenotype | 1 | 2020 | 4037 | 0.02 | Why? |
| Loneliness | 1 | 2020 | 1766 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Congresses as Topic | 1 | 2017 | 1347 | 0.02 | Why? |
| Politics | 1 | 2021 | 1824 | 0.02 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.02 | Why? |
| Residence Characteristics | 1 | 2018 | 1927 | 0.02 | Why? |
| Disabled Persons | 1 | 2018 | 1152 | 0.02 | Why? |
| Odds Ratio | 1 | 2019 | 5861 | 0.02 | Why? |
| New York City | 1 | 2020 | 7432 | 0.02 | Why? |
| Ambulatory Care Facilities | 1 | 2018 | 2063 | 0.02 | Why? |
| Social Support | 1 | 2017 | 3183 | 0.01 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.01 | Why? |
| Mortality | 1 | 2018 | 7132 | 0.01 | Why? |
| Health Status Disparities | 1 | 2018 | 4072 | 0.01 | Why? |
| Adaptation, Psychological | 1 | 2017 | 4996 | 0.01 | Why? |
| Quality of Life | 1 | 2019 | 9820 | 0.01 | Why? |
| Age Factors | 1 | 2019 | 21039 | 0.01 | Why? |
| Young Adult | 2 | 2018 | 93724 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Cardiovascular Diseases | 1 | 2021 | 11497 | 0.01 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2020 | 88759 | 0.01 | Why? |
| Aged | 1 | 2020 | 215776 | 0.00 | Why? |